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Abstract   
Therapeutic treatment of tuberculosis (TB) is becoming increasingly problematic due to the emergence 
of drug resistant Mycobacterium tuberculosis (Mt). Thus, new targets for anti-TB drug discovery need 
to be identified to combat and eradicate this disease. One such target is hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) which synthesises the 6-oxopurine nucleoside monophosphates 
essential for DNA/RNA production. [3R,4R]-4-Hypoxanthin-9-yl-3-((S)-2-hydroxy-2-
phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine and [3R,4R]-4-guanin-9-yl-3-((S)-2-
hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine (compound 6) are the most 
potent inhibitors of MtHGPRT yet discovered having Ki values of 60 nM. The crystal structure of the 
MtHGPRT.6 complex was obtained and compared with that of human HGPRT in complex with the 
same inhibitor. These structures provide explanations for the 60-fold difference in the inhibition 
constants between these two enzymes and a foundation for the design of next generation inhibitors. In 
addition, crystal structures of MtHGPRT in complex with two pyrrolidine nucleoside phosphosphonate 
inhibitors plus pyrophosphate provide insights into the final stage of the catalytic reaction.  As the first 
step in ascertaining if such compounds have the potential to be developed as anti-TB therapeutics, the 
tetra-(ethyl L-phenylalanine) tetraamide prodrug of 6 was tested in cell based assays. This compound 
arrested the growth of virulent Mt not only in its replicating phase (IC50 of 14 µΜ) but also in its latent 
phase (IC50 of 29 µΜ). Furthermore, it arrested the growth of Mt in infected macrophages (MIC50 of 
85 µΜ) and has a low cytotoxicity in mammalian cells (CC50 of 132 ± 20 µM). These inhibitors are 
therefore viewed as forerunners of new anti-TB chemotherapeutics.  
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1. Introduction 
  Mycobacterium tuberculosis (Mt) is the predominant etiological agent for human tuberculosis 
(TB).1 TB remains a global public health threat, with 10 million cases of active disease per annum 
resulting in 1.8 million deaths.2 Current treatment for TB is a standard six-month regimen of 
rifampicin and isoniazid, supplemented with pyrazinamide and ethambutol in the first two months.3 
However, the emergence of multidrug-resistant Mt (MDR-TB)4 and extensively drug-resistant Mt 
(XDR-TB)5 has limited the capacity to eradicate this disease. A major obstacle in eradication is the 
development of drugs that efficiently target both the replicating and non-replicating/dormant stages of 
Mt.6 For example, when in dormancy, Mt is insensitive to the frontline drug, isoniazid.7 Thus, there is 
an urgent need for new cost-effective TB therapeutics directed against not only the replicating stage of 
this pathogen but also its dormant (latent/persistent) stage. Crucially, apart from bedaquiline, which 
has associated toxicity concerns8 and is currently the subject of clinical investigation,9-10 it has been 
more than 50 years since a new therapeutically viable anti-TB drug was commercially introduced onto 
the market.11  
Evidence that hypoxanthine-guanine phosphoribosyltransferase is a target for the development 
of anti-TB therapeutics comes from two sources.  The first is a random transposon mutagenesis study 
which showed that the expression of this enzyme is essential for the survival of Mt.12 The second is a 
recent study which showed that prodrugs of inhibitors of Mt hypoxanthine-guanine 
phosphoribosyltransferase (MtHGPRT) activity arrested the growth of a virulent strain of Mt in cell 
culture.13  Thus, began the search for the design of new and more potent inhibitors which could also 
posses anti-TB activity.  
MtHGPRT catalyses the formation of the nucleoside monophosphates, IMP or GMP, and 
pyrophosphate (PPi). The substrates are 5-phospho-α-D-ribosyl-1-pyrophosphate (PRib-PP) and 
hypoxanthine (Hx) or guanine (G); xanthine is not a substrate.13-14 For catalysis to occur, a divalent 
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metal ion, usually magnesium, is required (Fig. 1). Literature reports suggest that the mechanism of 
action of MtHGPRT is ordered and sequential,15 similar to that of human HGPRT.16 However, the 
kinetic parameters for the two enzymes are very different. PRib-PP, for example, has a much higher 
Km for MtHGPRT than for human HGPRT with values of 465 µM with guanine as the base and 1443 
µM with hypoxanthine as the base13-14 compared with 60 µM and 30 µM, respectively, for human 
HGPRT.16-17 The values for the purine bases, however, differ by only two-fold with the Km for guanine 
and hypoxanthine being 4.4 and 8.3 µM for MtHGPRT13, 17 while, for human HGPRT, these values are 
1.9 and 3.4 µM,17 respectively. The kcat values for these two enzymes in the forward reaction are also 
widely different. MtHGPRT has a kcat values of 0.6 s-1 (guanine as base) and 0.5 s-1 (hypoxanthine as 
base)13 while, for human HGPRT, the kcat values are 10-fold higher, 8.2 s-1 (guanine) and 5.2 s-1 
(hypoxanthine).17 The tetrameric structure of both enzymes also differ in the arrangement of their 
subunits. Thus, in the quaternary structure of the human enzyme, the large mobile loop which moves 
to cover the active site during catalysis is located on the outside of the structure where, in its open 
position, it is exposed to solvent. In contrast, this loop is buried at the interface of the dimer pairs in 
MtHGPRT.13 Whether this structural arrangement has an effect on the kinetic constants is, however, 
unknown at present.   
 
Fig. 1. The reaction catalysed by MtHGPRT. R = -H (hypoxanthine); -NH2 (guanine). The other 
naturally-occurring purine base, xanthine (R = -OH), is not a substrate.13-14  
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The only reported inhibitors of MtHGPRT to date are the acyclic nucleoside phosphonates 
(ANPs).13 Their structure consists of a phosphonate moiety connected to a nucleobase via an acyclic 
linker. The advantage of using these compounds as a template for therapeutics is the presence of the 
carbon phosphorus bond within the phosphonate moiety which makes them enzymatically and 
chemically stable within the cell.18 The genesis for these potential anti-TB drugs is based on structure 
of the successful antiviral agent tenofovir that was developed by Antonin Holý and colleagues.18 
Prodrugs of the ANPs arrest the growth of Pf in cell culture19-21 highlighting the possibility that 
selective design could lead to the development of chemotherapeutics against Mt where the activity of 
this enzyme also appears to be essential for the survival and reproduction of this organism.  
Pyrrolidine nucleoside monophosphonates (PNPs) inhibit the two 6-oxopurine PRTases from 
Escherichia coli, XGPRT and HPRT,22 Plasmodium falciparum HGXPRT19, Plasmodium vivax 
HGPRT 19 and human HGPRT.19, 22 In these compounds, a purine base is attached to a phosphonate 
moiety via a pyrrolidine ring in the linker which connects the two functional groups. The five 
membered pyrrolidine ring is connected to the N9 atom of the purine base (Fig. 1), as is the ribose 
moiety of the products of the catalytic reaction, GMP and IMP. The basic structure of this class of 
inhibitor is shown in Fig. 2 indicating their structural diversity and how and where chemical 
modifications can be made to increase their potency for the 6-oxopurine phosphoribosyltransferases 
from different organisms.  For example, different chemical attachments can be made at the carbon (R1) 
and/or the nitrogen (R2) position of the pyrrolidine ring (Fig. 2).  
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Fig. 2. The chemical structure of the phosphonates which contain a pyrrolidine ring in the linker. 
The pyrrolidine group can be attached to any purine base at the 9-position in the imidazole ring. 
R1 and R2 denote where different chemical moities can be attached to the pyrrolidine ring. In the 
two pyrrolidine nucleoside monophosphonates (PNPs) described here, a phosphonate group is 
attached at the R1
 
position and, in the pyrrolidine nucleoside bisphosphonates (PNBPs), a second 
phosphonate group is attached at R2. The (*) shows the stereocenters. 
In this report, eight compounds containing a pyrrolidine group in the acyclic linker were 
trialled as inhibitors of MtHGPRT (Fig. 3). Two of these belong to the purine nucleoside 
monophosphonate (PNP) class of compounds while six belong to the pyrrolidine nucleoside 
bisphosphonates (PNBPs) class.  The first class contains a single phosphonate group while the second 
contains two phosphonate groups. X-ray crystal structures of the two PNPs, ([3R,4R]-(4-(hypoxanthin-
9-yl)pyrrolidin-3-yl)-oxymethanephosphonic and [3R,4R]-(4-(guanin-9-yl)pyrrolidin-3-
yl)oxymethanephosphonic acid were obtained in complex MtHGPRT in the presence of 
pyrophosphate. The X-ray structure of one of the PNBPs, ([3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-
phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine) (6) in complex with MtHGPRT was also 
obtained.  This structure was then compared with that of the human counterpart in complex with the 
same inhibitor to explain the 60-fold difference in the Ki values and to provide the necessary tools to 
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improve their design aimed at increasing potency for MtHGPRT.  In order to determine if such 
coumpounds have the potential for further development as anti-TB agents, a tetra-(ethyl L-
phenylalanine) tetraamide prodrug of 6 was tested against TB in cell culture. These studies were done 
under aerobic (reflecting the replicating stage of its life cycle) and hypoxic (reflecting its dormant 
stage) conditions. The effect of this prodrug on the growth of the bacillus in infected macrophages and 
its cytotoxicity in mammalian cells in vivo were also determined.  
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2. Results and Discussion 
2.1.  Chemistry 
Figures 3 and 4 give the chemical structures of the eight compounds examined in this study. 
The synthesis and chemical analysis of 1, 2, 5, 6 and 8 have been reported previously.19, 22 The 
methodology for the synthesis of 3, 4, and 7 is presented in Scheme 1; the synthesis of the new 
compounds 3, 4, and 7 follows the same experimental procedures described in a previous report.23 
                                                                     
1 (B = Hx); 2 (B = guanine) 
Fig. 3. The pyrrolidine nucleoside phosphonates (PNPs) where the purine base (B) is either 
hypoxanthine or guanine.  1: [3S,4R]-(4-(Hypoxanthin-9-yl)pyrrolidin-3-yl)-oxymethanephosphonic 
acid; 2: [3S,4R]-(4-(Guanin-9-yl)pyrrolidin-3-yl)oxymethanephosphonic acid.   
Fig. 4. The pyrrolidine nucleoside bisphosphonates (PNBPs) where the purine base (B) is either 
hypoxanthine or guanine: [3R,4S]-4-hypoxanthin-9-yl-3-(2-phosphonoethyl)oxy-1-N-
(phosphonopropionyl)pyrrolidine (3), [3R,4S]-4-guanin-9-yl-3-(2-phosphonoethyl)oxy-1-N-
(phosphonopropionyl)pyrrolidine (4), [3R,4R]-4-hypoxanthin-9-yl-3-((S)-2-hydroxy-2-
phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine (5),  [3R,4R]-4-guanin-9-yl-3-((S)-2-
hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine (6), [3R,4R]-4-hypoxanthin-9-
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yl-3-((R)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine (7), and [3R,4R]-4-
guanin-9-yl-3-((R)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine (8). 
Scheme 1. Synthetic scheme for compounds 3, 4, and 7. 
2.2. Inhibition of MtHGPRT activity 
The Ki values of the eight compounds for MtHGPRT are given in Table 1. These values are 
compared with those for human HGPRT. 
Table 1. The Ki values for the pyrrolidine inhibitors of MtHGPRT and human HGPRT 
Code 
        Ki (µM) 
Mt                      Human 
Base is hypoxanthine 
Ki ratio 
Mt/human 
Code 
           Ki (µM) 
      Mt                  Human 
Base is guanine 
Ki ratio 
Mt/human 
1 88±4             327±70  0.3 2 8±0.4            29±10    0.3 
1   3 ± 4a            NDb - 2 0.74±0.1a           NDb    ND 
3 0.42±0.04     0.6±0.06  0.7 4 0.04±0.01      0.03±0.01    1.3 
5 0.06±0.004  0.001±0.0007c      60 6c 0.06±0.01      0.003±0.001c   20 
7 0.20±0.02     0.008±0.002c      25 8c 0.13±0.01      0.008±0.003c   16 
aAddition of 400 µM pyrophosphate to the assay. bND = not determined. c see reference 19 
These eight compounds exhibit a wide range of selectivity in their Ki values for MtHGPRT and 
human HGPRT, 0.3 to 60 fold (Table 1).  Compounds 1 and 2 have much lower Ki values for 
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MtHGPRT compared with human HGPRT (ratio of 0.3), compounds 3 and 4 do not discriminate 
(ratios of 0.7 and 1.3) while, for compounds 5 and 6 as well as compounds 7 and 8, the selectivity is 
reversed with the Ki values being lower for human enzyme compared with MtHGPRT (ratios of 16 to 
60) (Table 1).  Together with the dissimilarities in the kinetic constants for the naturally-occurring 
substrates, this data suggests differences in the structure of their active sites.  
Table 1 shows that the chemical nature of the phophonate moiety effects the Ki values.  
Furthermore, it also appears to effect how the purine bases bind. For example, compounds 1, 2, 3 and 
4, have lower Ki values for both enzymes when guanine is the base but, for compounds 5, 6, 7 and 8, 
the Ki values are similar, irrespective of whether the base is guanine or hypoxanthine (Table 1).  
PPi, at a concentration of 400 µM in the assay, does not inhibit MtHGPRT activity (cf. 5.7 
nmoles min-1 in its absence with 6.6 nmoles min-1 in its presence).  However, when PPi is added to the 
assay together with either of the PNPs (1 or 2), the Ki value for the PNP decreases by 30- and 11- fold 
(Table 1), suggesting that PPi binds in the active site together with 1 or 2, thus effecting the kinetic 
constants.  The decrease in the Ki values could occur by PPi, re-positioning the PNP to a more optimal 
location. Schramm and his colleagues have demonstrated that the tight binding complexes of the 
transition state analogs, immucillin-G 5′-phosphate or immucillin-H 5′-phosphate with human HGPRT 
and PfHGXPRT, respectively, are only obtained in the presence of MgPPi as all three sites need to be 
occupied.24-26 The Ki values are significantly lower for MtHGPRT with compounds 3, 4, 5, 6, 7 and 8 
compared with 1 and 2 (220-1466 fold, hypoxanthine as base; 61-200 fold, guanine as base). These 
ratios fall to 7.5-50 and 5-20 when PPi is added to the assay with compounds  1 and 2. Thus, a 
reasonable proposition is that the primary reason for this large decrease is due to the attachment of a 
second covalently linked phosphonate group to compounds 3, 4, 5, 6, 7 and 8. This second 
phosphonate group would then be expected to occupy the PPi binding site. The Ki values for 
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MtHGPRT of 4, 5 and 6 are the lowest yet determined for this enzyme (Table 1) as the best previous 
value is 1 µM.13  
Crystal structures of MtHGPRT in complex with 1, 2 or 6 were, therefore, obtained to explain 
how these inhibitors bind in the active site so as to be able to modify their design to produce 
compounds with even lower Ki values.  The structures of the MtHGPRT.6 complex and the human 
HGPRT.6 complex were compared to discover if differences exist in their mode of binding in their 
active sites. 
2.3. Crystal structures of MtHGPRT in complex with two PNPs and a BPNP. 
2.3.1. Overall structure.  
  Crystal structures of MtHGPRT in complex with 1 plus PPi, 2 plus PPi and 6 were determined 
at 2.44 Å, 2.55 Å and 2.91 Å resolution, respectively. The data collection and refinement statistics are 
presented in Table S1. All three complexes crystallized as a tetramer in the asymmetric unit and there 
is strong electron density for each of the inhibitors in all four active sites of the tetramer (Fig. 5). For 
compound 2, PPi was added directly to the enzyme, together with the inhibitor, five minutes before 
adding this mixture to the well solution.  For 1, however, PPi was not added to the enzyme though 
electron density corresponding to this structure was found in the active site. The presence of PPi in this 
structure appears to have arisen due to the magnesium catalysed hydrolysis of PRib-PP.27  MtHGPRT 
is stored in 0.1 M Tris-HCl, 0.012 M MgCl2, pH 7.4 containing 200 µM PRib-PP, -80 oC, under which 
conditions it is stable for >2 years.13 
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Fig. 5.  Fo-Fc omit electron density map and the structure of the three inhibitors overlayed onto the 
Connolly surface of MtHGPRT. (A) 1, (B) 2, (C) 6.  For simplification, the electron density for PPi in 
the active site has not been included in Figs. 5A and B. 
The RMSD values upon superimposition of Cα atoms in these three complexes are presented in 
Table S2. These data show that there are only minimal differences in the overall fold (0.22 to 0.36 Å) 
when the three structures are compared. When dimer halves of MtHGPRT are superimposed (lower 
diagonal), the RMSD values are only marginally smaller and range from 0.22 to 0.37 Å. This suggests 
that the presence of inhibitors in the active site does not influence the association of the four subunits. 
Thus, the differences in affinity of the three pyrrolidine inhibitors are not due to major structural 
changes in the enzyme.  
2.3.2. The active site of MtHGPRT 
Fig. 6 identifies key areas of MtHGPRT proposed to be involved in binding of key functional 
groups.  These areas are based on the amino acid sequence and deductions from known crystal 
structures.13 Figs. 7, 8 and 9 show the specific interactions that the atoms of each of the three inhibitors 
form with active site residues. 
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Fig. 6. Amino acid sequence of MtHGPRT. The chemical structure of 6 is inserted in this figure 
to show where functional groups would be expected to bind. The residues contained in the large 
mobile loop proposed to close over the active site during catalysis (residues V90-L106) are 
shown  in blue. 
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Fig. 7. Stereoview of the active site of the MtHGPRT.1.PPi complex. Each subunit contains two 
molecules of pyrophosphate. (A) shows the location of one of the PPi molecules and (B) shows 
the location of the second. Solid spheres represent Mg2+ ions (green) and waters (red).  
 
Fig. 8. Stereoview of the active site of the MtHGPRT.2.PPi complex (subunit A). Compound 2 
has the carbon atoms in magenta and PPi is drawn in red and orange. There is only one PPi in 
each of the four active sites but it has two different orientations. Subunits A and B have one 
orientation while subunits C and D have the second.  Solid spheres represent the two Mg2+ ions 
(green) and waters (red) in the MtHGPRT.2.PPi complex. The structure of 1 and PPi (cyan) when 
bound to MtHGPRT is superimposed for comparison.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15
 
Fig. 9. Stereo view of the active site of the MtHGPRT.6 complex. (A) Subunit A (top: occupancy 
of 6 is 60%; bottom: occupancy of 6 is 40%). (B) Subunit B. The inhibitor has the same 
orientation in subunits B,  C and D and this is the same as the top panel in (A). The single Mg2+ 
ion and water molecules are shown as green and red spheres, respectively.  
 Figs. 10A and 10B compare the location of PPi in the MtHGPRT.1 or 2 complexes with that of 
PPi in human HGPRT.ImmGP.PPi complex.25  Fig. 10C compares the location of the phosphonate 
group pointing down into the predicted PPi  binding site in the MtHGPRT.6 with that of the 
phosphonate group in the human HGPRT.6 complex19 and the human HGPRT.ImmGP.PPi complex.25 
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Fig. 10. The pyrophosphate binding site in MtHGPRT. The crystal structures are 
superimposed on that of the HGPRT.ImmGP.PPi complex (yellow). (A) The location of the two 
PPi molecules present in all four subunits in the MtHGPRT.1.PPi complex. (B) The location of 
the single PPi molecule in subunits A and B (dark blue) or C and D (pale blue) in the 
MtHGPRT.2.PPi complex (C) Superimposition of MtHGPRT.6 (green) with human HGPRT.6 
(wheat).19 α and β correspond to the positions of the phosphorus atoms shown in Figs. 7 and 8. 
The red arrows in A and B show the rotation of the phosphorus atom (α).  
Superimposition of the three MtHGPRT structural complexes reveal the differences in the 
location of these three inhibitors in the active site. These lie in four areas: (i) the location and 
orientation of the pyrrolidine ring; (ii) the position of the phosphonate group located in the 5′-
phosphate binding pocket; (iii) the location and the number of magnesium ions; and (iv) the position of 
the purine base (Fig. 11). 
A B C
MtHGPRT.1.PPi MtHGPRT.2.PPi(subunits A and B)
MtHGPRT.2.PPi(subunits C and D)
β β
α
α β
MtHGPRT.6
Human
HGPRT.6
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Fig. 11. Comparison of the binding modes of 1, 2 and 6 in the active site of MtHGPRT (subunit 
D).  Connolly surface of the enzyme from the complex with 1 is overlaid.  Inhibitors 1, 2 and 6 
have carbon atoms coloured as magenta, cyan and green, respectively. The location of the 
divalent metal ions in the three structures are shown in magenta (1; two magnesium ions), cyan 
(2; two magnesium ions) and green (6; one magnesium ion). 
2.3.3. The pyrrolidine ring  
The pyrrolidine ring covalently connects the three functional groups. Though the atoms in the 
ring do not make any interactions with active site residues (Figs. 7, 8 and 9), the chemical structure of 
the ring itself is critical in placing these groups in the predicted binding sites.28 
  The presence of the rotatable bond between the N9 atom of the purine ring and the C1′ atom of 
the pyrrolidine ring in 619 allows for either one of the two phosphonate groups (attached at R1 or R2; 
Fig. 2) to be placed in the two areas in the active site able to bind a phosphate group i.e. the 5′-
phosphate or the PPi binding sites.  In the MtHGPRT.6 complex, the phosphonate group attached to the 
nitrogen in the pyrrolidine ring (R2) occupies the 5′-phosphate binding pocket in subunits B, C and D 
1 
1 
2 
2 
6 
6 
6 
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(Fig. 9B).  However, in subunit A, a second orientation occurs 40% of the time (Fig. 9A) with the 
phosphonate group at R1 occupying the binding site of the 5′-phosphate group of GMP. It is this latter 
orientation that 6 adopts when it binds to human HGPRT (Fig. 12B).19  
 
Fig. 12. Comparison of the binding modes of 6 in the active site of MtHGPRT and human HGPRT. 
Connolly surface of MtHGPRT is overlaid in both panels. (A) Superimposition of the two different 
orientations of 6 in subunit A of MtHGPRT. There is only one magnesium ion (magenta) in this 
subunit. In the least favoured orientation of compound 6 (blue), this ion is coordinated to the carbonyl 
group in the linker and to one of the phosphonyl oxygens (blue dashes) while, in the most favoured 
(yellow), it is coordinated to a phosphonyl oxygen (red dashes). (B) Superimposition of MtHGPRT.6 
(subunit B; yellow) with human HGPRT.6 (green; PDB code: 5HIA).19 Magenta is the single 
magnesium ion in the MtHGPRT.6 complex; green is the two magnesium ions in the human HGPRT.6 
complex. The two invariant ED residues (122-123 in MtHGPRT and 133-134 in human HGPRT) are 
in magenta (MtHGPRT.6 complex) and green (human HGPRT.6 complex). It is hypothesised that it is 
the movement of mobile loops in the two enzymes which determine how 6 binds in the active site.  
2.3.4. The two phosphonate groups. 
  The 5′-phosphate binding pocket. The phosphonate group found in the predicted 5′-phosphate 
binding pocket when each of the three inhibitors binds to MtHGPRT is surrounded by a flexible loop, 
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residues D126-T130 (Figs. 7, 8 and 9). This phosphonate group pushes deepest into this pocket when 
the compounds exhibit the lowest Ki values i.e.  6 > 2 > 1 (Table 1; Fig. 11). The location of this 
group when compounds 1 and 2 bind results in empty space at the bottom of this pocket which is filled 
by water molecules (Figs. 7 and 8). Thus, the third phosphonyl oxygen forms hydrogen bonds to three 
water molecules. This generates an extensive network of hydrogen bonds which helps to anchor the 
two inhibitors in the active site. One of these waters forms part of a series of hydrogen bonds to other 
water molecules one of which is coordinated to the magnesium atom that is liganded to E122 and 
D123  (Figs. 7 and 8). 
As the phosphonate group of 6 pushes deeper into the 5′-phosphate binding pocket (subunits B, 
C and D; Fig. 9), it occupies most of the available space in this cavity leaving no room for water 
molecules. It is possible that the changes in the hydrogen bond network due to the absence of water 
molecules could be one reason why the side chains of the ED residues have not been able to move the 
ligand to a magnesium ion as found in the MtHGPRT.1 and MtHGPRT.2 complexes.  
In the MtHGPRT.6 complex, the flexible loop (D126-T130) is itself surrounded by two loops 
(K154-V162 and I171-D174) (Fig. 13).  Residues P155-H159 form an α-helix which joins two 
random coils (K154-P155 and H159–V162). In comparison, the corresponding loop in the human 
HGPRT.6 complex, T167-V171, is a simply a random coil and is further away from the 5′-phosphate 
binding loop (Fig. 13). D137 acts as general acid/base in catalysis in human HGPRT29 and D126 
probably performs the same function in MtHGPRT.15 Thus, the OD atom of D137 forms a hydrogen 
bond with N7 of the purine base in the transition state of catalysis. If the structure of the two 
MtHGPRT.6 complexes represents that prior to catalysis, then four bonds would have to be broken 
before D126 could move into position to form a hydrogen bond with the N7 atom (Fig. 13). These are 
between the OD atom of D126 to OD1 (N173), to two OD atoms (D156) and between the OD1 atom 
of D156 and N173.  In comparison, only one bond has to be broken in the human structure and this is 
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between OD of D137 and OE of R169 (Fig. 12). This pattern of hydrogen bonds may contribute to the 
lower kcat for MtHGPRT. 
The phosphonate group has to bend down into this pocket in the MtHGPRT.6  complex (Fig. 
13). This suggests that the loops surrounding D126-T140 restrict the movement of the D126-T140 
loop and, thus, the inhibitor itself has to adapt its shape to fit in this pocket.  
 
Fig. 13. Comparison of the structure of the 5′-phosphate binding pocket in the MtHGPRT.6 (blue) and 
human HGPRT.6 (orange; PDB code, 5HUI)19 complexes and the surrounding loop. The 5′-phosphate 
binding loop is DSGLT (126-130) in MtHGPRT and DTGKT (137-141) in human HGPRT. 
2.3.5. The pyrophosphate binding pocket     
  The addition of PPi to the assay for MtHGPRT together with the compounds 1 and 2 
significantly decreases the Ki values (Table 1) suggesting that PPi binds in the active site 
together with the inhibitor. The reaction mechanism of MtHGPRT is reported to be ordered 
sequential15 and, so, PPi cannot enter the active site alone and has to exit before GMP/IMP in the 
forward reaction or after GMP/IMP in the reverse reaction. Superimposition of the structures of 
the MtHGPRT.1 and 2 complexes onto that of the human.ImmGP.PPi structure25 (Figs. 10A and 
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10B) shows that one of the two PPi molecules found in the active site of the MtHGPRT complexes 
mimics that of pyrophosphate during the transition state of catalysis.  The location of the second 
PPi molecule is proposed to reflect its position immediately prior to, or just, after catalysis.  
.  Figs. 10A and B suggest that the β phosphate group of PPi is the first to enter or leave the 
active site.  The α phosphate group rotates around the phosphorus-oxygen bond resulting in this 
phosphorus atom moving by 3.7 Å.  In all three complexes, the side chain of K66 points away from the 
active site and towards the adjacent subunit. This occurs even in subunits A and B of the 
MtHGPRT.2.PPi complex, where a single pyrophosphate molecule is present and is entering the site. In 
subunit A, one of the phosphoryl oxygens (α phosphate group; Fig. 10B) forms a hydrogen bond the 
NZ atom of K66. This hydrogen bond between one of the oxygen atom on the α phosphate group also 
occurs in subunits C and D of the MtHGPRT.1.PPi complex. This could suggest that, unlike human 
HGPRT, there is no rotation of the lysine side chain in MtHGPRT (K66 in MtHGPRT and K68 in 
human HGPRT) when PPi enters the active site because, in the Mt enzyme, this side chain is already in 
position.  This hypothesis was previously proposed based on the oligomeric states of MtHGPRT.30 The 
structures of MtHGPRT in complex with 1 or 2 in the presence of PPi appear to provide further 
validation for this proposition. In the unliganded structure of EcHPRT, and in complex with IMP, the 
corresponding K residue is also rotated out of the PPi binding site.31 Thus, in this respect, the two 
bacterial enzymes could be similar and differ from human HGPRT. 
In the MtHGPRT.1.PPi complex, one of the phosphoryl oxygens is located 3 Å away from the 
nitrogen atom in the pyrrolidine ring suggesting that pyrophosphate is helping the inhibitor to bind in 
its optimal location.  This is consistent with the 27-fold derease in the Ki value which occurs in the 
presence of this second product of the reaction (Table 1).  
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2.3.6.  The large mobile loop 
  In the human HGPRT, a large mobile loop (L100-G117) closes over the active site during 
catalysis. This is shown by the structure of human HGPRT (PDB code: 1BZY) in complex with a 
transition state analog, ImmGP. In MtHGPRT, the corresponding residues are V90-L106 (Fig. 6). 
However, there are no structures of MtHGPRT where this loop is “closed” so it is not proven if this 
loop does, or can, close. For human HGPRT, the amino acid residues in this loop are only visualized 
during the transition state of the catalytic reaction25 but, for MtHGPRT, the amino acid residues in the 
flexible loop are resolved in all three inhibitor complexes (Table S1). The only known crystal structure 
where this loop is closed just in the presence of an inhibitor that is not mimicking the transition state of 
the reaction is that of PfHGXPRT in complex with an acyclic immucillin phosphonate plus 
pyrophosphate and magnesium.26 
In the MtHGPRT structures, an α-helix of five residues (S96-S100) is inserted in the random 
coil (Figs. 14A and B). For this loop to close over the active site during catalysis, this α-helix 
presumably would have to unravel and then re-form after the products are released. The Cα backbone 
would start to move to occupy an interim position such as the EcHPRT.1 structure (Fig. 14B)31 before 
reaching its final conformation and location which is assumed to be completely over the active site as 
in the human HGPRT.ImmGP.PPi complex.25  
In all three structures of MtHGPRT in complex with the inhibitors, the amino acids in the loop 
do not form any interactions with the inhibitor. Instead, they form hydrogen bonds with amino acid 
residues in adjacent subunits as has been observed previously in the MtHGPRT.GMP complex.13 The 
inter-subunit interactions may make it more difficult for the loop to fully close.  
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Fig. 14. Comparison of the large mobile loop structures in MtHGPRT and human HGPRT. A.  
Structure of MtHGPRT.2.PPi (subunit A, orange) superimposed with the structure of 
MtHGPRT.GMP.PPi (PDB: 4RHT subunit A, white).13 B.  The movement of the large mobile 
loop. Magenta: MtHGPRT.6, residues S91-R104.  Green: EcHPRT.1 (PDB code: 5KNX), 
residues S91-R104.31 Grey: Human HGPRT.ImmGP.PPi (PDB code: 1BZY), residues K102-
K114.25 Y is the conserved tyrosine residue (Mt, Y93; Ec, Y74; human, Y104). The arrows show 
the distance between the position of three amino acid residues (yellow) in loop in the three 
structures: S95 (MtHGPRT) to S76 (EcHPRT) is 9.2 Å, and S76 (EcHPRT) to N106 (human). 
Insert: The mobile loop in human HGPRT (Blue: PDB code: 5HIA)19 and MtHGPRT (magenta) 
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in complex with 6. The “closed” position of this loop in the HGPRT.ImmGP.PPi complex is 
shown for comparison.  
2.4. In vitro cell culture studies.   
The first step in assessing if potential compounds warrant further investigation and development 
as anti-TB chemotherapeutics is to assess their ability to arrest the growth of Mt in cell culture.  As 6 is 
highly negatively charged at neutral pH, this restricts the ability of the compound to cross cell 
membranes.  Therefore, for this type of drug, hydrophobic groups are rountinely attached to the 
phosphonate moieties to enhance delivery to the cell of interest.32-33 In this instance, the tetra-(ethyl L-
phenylalanine) tetraamide prodrug of 6 was chosen (Fig. 15A).  Once within the cell, the attached 
groups are hydrolysed by constitutive enzymes to produce the active inhibitor, 6, together with 
phenylalanine. This prodrug arrests the growth of Mt (H37Rv strain) with MIC90 values of 14 µM 
under conditions that mimic replicative growth (Fig. 15B). In latent TB, the mycobacteria lies dormant 
in caseous lesions of the lungs where there is little access to oxygen.34-35 Therefore, to mimic the latent 
stage, the prodrug was tested against the growth of Mt H37Rv under hypoxic conditions resulting in an 
MIC90 of 29 µM (Figure 15B), only a two-fold increase compared to the replicative stage. In the 
intramacrophage Mt H37Rv assay in vitro, the prodrug exhibited an MIC90 value of 85 µM. Against a 
mammalian cell line (A549), it exhibited a CC50 value of 132 ± 20 µM. 
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Fig. 15. Anti-TB activity of the tetra-(ethyl L-phenylalanine) tetraamide prodrug of 6 in Mt 
(H37Rv strain). A. Chemical structure of the prodrug. B. Inhibition of growth of Mt by the 
prodrug. The black dots represent the cell-based assay preformed under normal conditions while 
the red squares represent the assay results performed under hypoxic conditions.  
Thus, the prodrug is active against Mt not only when it is in its replicative stage but also 
when it is in its dormant phase. This is a very desirable property for any potential anti-TB drug 
candidate.  
Conclusions 
The pyrrolidine nucleoside monophosphonates, [3R,4S]-(4-(hypoxanthin-9-yl)pyrrolidin-3-yl)-
oxymethanephosphonic acid and [3R,4S]-(4-(guanin-9-yl)pyrrolidin-3-yl)oxymethanephosphonic 
acid, are micromolar inhibitors of the anti-TB drug target, hypoxanthine-guanine 
phosphoribosyltransferase.  Crystal structures of MtHGPRT in complex with these two 
inhibitors, plus PPi, reveal the route whereby PPi enters and leaves the active site prior to, or 
after, catalysis. They also show the location of this molecule during the transition state of the 
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reaction. The pyrrolidine nucleoside bisphosphonates (PNBPs) are the best inhibitors of 
MtHGPRT yet discovered with Ki values between 40-60 nM. The X-ray crystal structures of  
MtHGPRT and human HGPRT in complex with [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-
phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine show the different binding modes in 
the two active sites.  It is proposed that it is the movement and/or structures of flexible loops 
surrounding the active site that dictates how these compounds bind.  To enhance cell 
permeability, a tetra-(ethyl L-phenylalanine) tetraamide prodrug of this compound was prepared. 
The first step in drug development is to test if the compound of interest is effective against TB in 
cell culture. This produg not only arrested the growth of TB in a virulent strain but an extra 
bonus in this study was the finding that the prodrug was also active against Mt during bacterial 
dormancy.  This is a rare occurence for any potential anti-TB drug and a much sought-after 
property of such drugs. This prodrug is also effective against intramacrophage Mt H37Rv cells 
and has low cytotoxicity in human cell lines. Studies are now proposed to modify the inhibitor 
design based on the crystal structures and to improve the prodrug design specifically for TB cells 
as produgs of phosphonate compounds have yet to be designed to penetrate the TB cell 
membranes in particular. This data forms a solid foundation for the production of new anti-TB 
therapeutics.  
3. Experimental 
3.1.  Synthesis and Analytical Chemistry 
The chemical synthesis of compounds 1 and 223 was performed according to previously published 
methods as was that of compounds 5, 6, and 8.19 The synthesis of the prodrug of 6 has been also 
reported.19 
Unless stated otherwise, all solvents used were anhydrous.  TLC was performed on silica gel pre-
coated aluminium plates Silica gel/TLC-cards, UV 254 (Fluka) and compounds were detected by UV 
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light (254 nm), by heating (detection of dimethoxytrityl group; orange color), by spraying with 1% 
solution of ninhydrine to visualize amines, or by spraying with 1% solution of 4-(4-
nitrobenzyl)pyridine in ethanol followed by heating and treating with gaseous ammonia (blue color of 
mono- and diesters of phosphonic acid).  Preparative column chromatography was carried out on silica 
gel (40-60 µm; Fluka) and elution was performed at the flow rate of 40 ml/min.  The following solvent 
systems were used for TLC and preparative chromatography: toluene-ethyl acetate 1:1 (T); 
chloroform-ethanol 9:1 (C1); ethyl acetate-acetone-ethanol-water 6:1:1:0.5 (H3); ethyl acetate-
acetone-ethanol-water 4:1:1:1 (H1). The concentrations of solvent systems are stated in volume 
percent (% v/v).  Purity of prepared compounds was determined by LC-MS performed on Waters Auto 
Purification System with 2545 Quaternary Gradient Module and 3100 Single Quadrupole Mass 
Detector using LUNA C18 column (Phenomenex, 100 x 4.6 mm, 3 µm) at a flow rate of 1 ml/min.  
Purity of prepared final compounds was  > 95%. Typical conditions were: mobile phase, A – 50 mM 
NH4HCO3; B - 50 mM NH4HCO3 in 50% aq. CH3CN; C – CH3CN; A→B/10 min, B→C/10 min, C/5 
min. Preparative reverse phase HPLC (rpHPLC) was performed on a LC5000 Liquid Chromatograph 
(INGOS-PIKRON, CR) using a Luna C18 (2) column (250 x 21.2 mm, 5 µm) at a flow rate of 10 
ml/min by gradient elution of methanol in 0.1M TEAB pH 7.5 (A = 0.1M TEAB; B = 0.1M TEAB in 
50% aq. methanol; C = methanol) or without buffer.  Final compounds were lyophilized from water.  
Mass spectra were recorded on LTQ Orbitrap XL (Thermo Fisher Scientific) using ESI ionization.  
NMR spectra were measured on Bruker AVANCE 400 (1H at 400 MHz, 13C at 100.6 MHz), Bruker 
AVANCE 500 and Varian UNITY 500 (1H at 500 MHz, 13C at 125.8 MHz) spectrometers.  D2O 
(reference (dioxane) = 1H 3.75 ppm, 13C 69.3 ppm. Chemical shifts (in ppm, d scale) were referenced 
to TMS as an internal standard; coupling constants (J) are given in Hz.  All intermediates were 
determined by LC-MS. 1-N-Boc-3-dimethoxytrityloxy-4-hydroxypyrrolidines (all configurations) 
were prepared according to a previously established procedure. 
3.2. [3S,4R]-4-Hypoxanthin-9-yl-3-phosphonoethyloxy-1-N-(phosphonopropionyl)pyrrolidine (3) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 28
Title compound was prepared using the same methodology as described previously19, starting from 
[3S,4S]-3-dimethoxytrityloxy-1-N-Boc-4-hydroxypyrrolidine (0.9 g, 1.71 mmol) in 8% overall yield 
(79.5 mg, 0.14 mmol) in the form of white  amorphous solid. 
~ 6:7 mixture of rotamers A:B 
1H NMR (500.0 MHz, D2O, ref(dioxane) = 3.75 ppm, 25 °C): 1.58-1.81 (m, 4H, OCH2CH2P-A,B); 
1.81 – 1.91 (m, 4H, COCH2CH2P-A,B); 2.59 – 2.70 (m, 4H, COCH2CH2P-A,B); 3.46-3.61 (m, 2H, 
OCHaCHbCH2P-A,B); 3.68-3.78 (m, 3H, H-5′b-A, OCHaCHbCH2P-A,B); 3.82 (dd, 1H, Jgem = 11.9, 
J5′b,4′ = 4.3, H-5′b-B); 3.84 (dd, 1H, Jgem = 13.2, J5′a,4′ = 5.4, H-5′a-A); 4.05 (dd, 1H, Jgem = 12.6, J2′b,3′ = 
6.9, H-2′b-B); 4.07 (dd, 1H, Jgem = 11.9, J5′a,4′ = 5.5, H-5′a-B); 4.13 (dd, 1H, Jgem = 12.6, J2′b,3′ = 7.7, H-
2′a-B); 4.24 (dd, 1H, Jgem = 11.2, J2′b,3′ = 7.6, H-2′b-A); 4.29 (dd, 1H, Jgem = 11.2, J2′a,3′ = 7.6, H-2′a-
A); 4.50 (ddd, 1H, J4′,5′ = 5.4, 3.7, J4′,3′ = 4.7, H-4′-A); 4.56 (ddd, 1H, J4′,5′ = 5.5, 4.3, J4′,3′ = 4.8, H-4′-
B); 5.40 (ddd, 1H, J3′,2′ = 7.6, 6.9, J3′,4′ = 4.8, H-3′-B); 5.21 (td, 1H, J3′,2′ = 7.6, J3′,4′ = 4.6, H-3′-A); 8.22 
(s, 2H, H-2-A,B); 8.25 (s, 1H, H-8-B); 8.28 (s, 1H, H-8-A). 
13C NMR (125.7 MHz, D2O, ref(dioxane) = 69.30 ppm, 25 °C): 25.95 (d, JC,P = 134.7, COCH2CH2P-
B); 25.99 (d, JC,P = 134.6, COCH2CH2P-A); 31.28 (d, JC,P = 2.4, COCH2CH2P-B); 31.36 (d, JC,P = 2.4, 
COCH2CH2P-A); 31.70 (d, JC,P = 129.1, OCH2CH2P-B); 31.71 (d, JC,P = 129.1, OCH2CH2P-A); 50.25 
(CH2-2′-B); 50.92 (CH2-2′-A); 52.13 (CH2-5′-A); 52.82 (CH2-5′-B); 56.87 (CH-3′-B); 57.90 (CH-3′-
A); 69.13 (d, JC,P = 2.4, OCH2CH2P-A); 69.32 (d, JC,P = 2.5, OCH2CH2P-B); 78.93 (CH-4′-A); 80.09 
(CH-4′-B); 125.79 (C-5-A); 125.84 (C-5-B); 143.74 (CH-8-B); 143.89 (CH-8-A); 148.55 (CH-2-A,B); 
152.04 (C-4-A); 152.09 (C-4-B); 161.41 (C-6-A,B); 177.21 (d, JC,P = 17.9, NCO-A); 177.29 (d, JC,P = 
17.9, NCO-B). 
31P[1H] NMR (202.3 MHz, D2O, ref (external H3PO4) = 0 ppm, 25 °C): 19.53 (PCH2CH2O-A); 19.58 
(PCH2CH2O-B); 23.20 (PCH2CH2CO-A); 23.29 (PCH2CH2CO-B). 
HRMS (ESI-) for C14H20N5O9P2 (M-H)- : calcd 464.07417, found 464.07417. 
3.3.  [3S,4R]-4-Guanin-9-yl-3-phosphonoethyloxy-1-N-(phosphonopropionyl)pyrrolidine (4) 
Title compound was prepared using the same methodology described previously,19 starting from 
[3S,4S]-3-dimethoxytrityloxy-1-N-Boc-4-hydroxypyrrolidine (1.18 g, 2,32 mmol) in 7% overall yield 
(291 mg, 0.51 mmol) in the form of white amorphous solid. 
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~ 6:7 mixture of rotamers A:B 
1H NMR (500.0 MHz, D2O, ref(dioxane) = 3.75 ppm, 25 °C): 1.64-1.83 (m, 4H, OCH2CH2P-A,B); 
1.83 – 1.91 (m, 4H, COCH2CH2P-A,B); 2.60 – 2.67 (m, 4H, COCH2CH2P-A,B); 3.52-3.83 (m, 7H, H-
5′-A, H-5′b-B, OCH2CH2P-A,B); 3.96 (dd, 1H, Jgem = 12.6, J2′b,3′ = 7.1, H-2′b-B); 4.02 (dd, 1H, Jgem = 
11.9, J5′a,4′ = 5.4, H-5′a-B); 4.07 (dd, 1H, Jgem = 12.6, J2′b,3′ = 7.7, H-2′a-B); 4.15 (dd, 1H, Jgem = 11.2, 
J2′b,3′ = 7.6, H-2′b-A); 4.23 (dd, 1H, Jgem = 11.2, J2′a,3′ = 7.6, H-2′a-A); 4.44 (ddd, 1H, J4′,5′ = 5.1, 3.7, 
J4′,3′ = 4.6, H-4′-A); 4.50 (dt, 1H, J4′,5′ = 5.4, 4.6, J4′,3′ = 4.6, H-4′-B); 5.15 (ddd, 1H, J3′,2′ = 7.7, 7.1, J3′,4′ 
= 4.6, H-3′-B); 5.21 (td, 1H, J3′,2′ = 7.6, J3′,4′ = 4.6, H-3′-A); 7.89 (s, 1H, H-8-B); 7.93 (s, 1H, H-8-A). 
13C NMR (125.7 MHz, D2O, ref(dioxane) = 69.30 ppm, 25 °C): 25.92 (d, JC,P = 134.7, COCH2CH2P-
B); 25.95 (d, JC,P = 134.7, COCH2CH2P-A); 31.21 (d, JC,P = 2.4, COCH2CH2P-B); 31.32 (d, JC,P = 2.4, 
COCH2CH2P-A); 31.65 (d, JC,P = 129.0, OCH2CH2P-B); 31.67 (d, JC,P = 129.0, OCH2CH2P-A); 50.08 
(CH2-2′-B); 50.82 (CH2-2′-A); 52.11 (CH2-5′-A); 52.76 (CH2-5′-B); 56.02 (CH-3′-B); 57.13 (CH-3′-
A); 69.17 (d, JC,P = 2.5, OCH2CH2P-A); 69.37 (d, JC,P = 25.0, OCH2CH2P-B); 78.88 (CH-4′-A); 80.05 
(CH-4′-B); 118.26 (C-5-A); 118.29 (C-5-B); 141.14 (CH-8-B); 141.34 (CH-8-A); 154.71 (C-4-A); 
154.76 (C-4-B); 156.48 (C-2-A,B); 161.68 (C-6-A,B); 177.13 (d, JC,P = 17.8, NCO-A); 177.17 (d, JC,P 
= 17.8, NCO-B). 
31P [1H] NMR (202.3 MHz, D2O, ref (external H3PO4) = 0 ppm, 25 °C): 19.73 (PCH2CH2O-A); 19.75 
(PCH2CH2O-B); 23.32 (PCH2CH2CO-A); 23.39 (PCH2CH2CO-B). 
HRMS (ESI-) for C14H21N6O9P2 (M-H)- : calcd 479.08507, found 479.08478. 
3.4. [3R,4R]-4-Hypoxanthin-9-yl-3-((R)-2-hydroxy-2-phosphonoethyl)oxy-1-N-
(phosphonopropionyl)pyrrolidine (7) 
Title compound was prepared using the same methodology as described previously, starting from 
diisopropyl ((R)-1-tert-butyldimethylsilyloxy-2-(((3R,4S)-1-N-boc-4-dimethoxytrityloxypyrrolidin-3-
yl)oxy)ethyl)phosphonate (compounds 10-R19) (0.31 g, 0.59 mmol) in overall 31% yield (56.9 mg, 0.1 
mmol) in the form of white amorphous solid. 
~ 6:7 mixture of rotamers A:B 
1H NMR (500.0 MHz, D2O, ref(dioxane) = 3.75 ppm, 25 °C): 1.81 – 1.94 (m, 4H, COCH2CH2P-A,B); 
2.60 – 2.71 (m, 4H, COCH2CH2P-A,B); 3.64 – 3.78 (m, 3H, H-5′b-A, OCHaHbCH(OH)P-A,B); 3.84 
(dd, 1H, Jgem = 12.1, J5′b,4′ = 3.6, H-5′b-B); 3.85-4.03 (m, 5H, H-5′a-A, CH(OH)P-A,B, 
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OCHaHbCH(OH)P-A,B); 4.08 (dd, 1H, Jgem = 13.3, J2′b,3′ = 4.5, H-2′b-B); 4.10-4.21 (m, 2H, H-2′a,5′a-
B); 4.22 (dd, 1H, Jgem = 12.2, J2′b,3′ = 4.7, H-2′b-A); 4.37 (dd, 1H, Jgem = 12.2, J2′a,3′ = 7.3, H-2′a-A); 
4.60 (dt, 1H, J4′,5′ = 5.9, 4.0, J4′,3′ = 4.0, H-4′-A); 4.65 (ddd, 1H, J4′,5′ = 5.9, 3.6, J4′,3′ = 3.9, H-4′-B); 
5.25 (ddd, 1H, J3′,2′ = 7.2, 4.5, J3′,4′ = 3.9, H-3′-B); 5.33 (ddd, 1H, J3′,2′ = 7.3, 4.7, J3′,4′ = 4.0, H-3′-A); 
8.12 (s, 1H, H-8-B); 8.17 (s, 1H, H-8-A); 8.20 (s, 2H, H-2-A,B). 
13C NMR (125.7 MHz, D2O, ref(dioxane) = 69.30 ppm, 25 °C): 25.93 (d, JC,P = 134.8, COCH2CH2P-
A,B); 31.31 (d, JC,P = 2.4, COCH2CH2P-A); 31.41 (d, JC,P = 2.4, COCH2CH2P-B); 50.79 (CH2-2′-B); 
51.67 (CH2-2′-A); 52.15 (CH2-5′-A); 53.03 (CH2-5′-B); 60.04 (CH-3′-B); 61.22 (CH-3′-A); 71.60 (d, 
JC,P = 150.7, CH(OH)P-A,B); 74.10 (d, JC,P = 11.0, OCH2CH(OH)P-A); 74.19 (d, JC,P = 11.0, 
OCH2CH(OH)P-B); 82.59 (CH-4′-A); 83.88 (CH-4′-B); 126.45 (C-5-A); 126.49 (C-5-B); 142.64 (CH-
8-B); 142.78 (CH-8-A); 148.52 (CH-2-A,B); 151.67 (C-4-A,B); 161.37 (C-6-A,B); 177.12 (d, JC,P = 
17.9, NCO-A); 177.21 (d, JC,P = 17.9, NCO-B). 
31P[1H] NMR (202.3 MHz, D2O, ref (external H3PO4) = 0 ppm, 25 °C): 15.17 (PCH(OH)CH2O-A); 
15.19 (PCH(OH)CH2O-B); 23.33 (PCH2CH2CO-A); 23.39 (PCH2CH2CO-B). C14H20N5O10P2 (M-H)- : 
calcd  480.06909, found 480.06833. 
3.5 Expression and purification of MtHGPRT 
Recombinant MtHGPRT was expressed and purified as previously described.13 The enzyme was 
subsequently stored in 0.1 M Tris-HCl, 12 mM MgCl2, pH 7.4, 200 µM PRib-PP at −80 °C where it is 
stable for > 2 years. 
3.6. Determination of Ki values 
Enzyme activity was determined using a continuous spectrophotometric assay, by measuring the 
conversion of guanine to GMP at 257.5 nm (∆ε = 5816.5 M-1 cm-1). The Ki values were determined in 
0.01 M phosphate buffer, 12 mM MgCl2, pH 7.4. The concentration of guanine was fixed at 60 µM 
and the concentration of the second substrate PRib-PP varying from 100−1500 µM depending on the 
Km(app) in the presence of the inhibitor. The concentration of inhibitor in the assays ranged from 80 nM 
to 6.6 µM, depending upon the potency of the particular compound. Ki values were calculated using 
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Prism4 (GraphPad Software, Inc., La Jolla, CA). For pyrophosphate, Ki(app) was calculated using the 
equations v=Vmax[S]o/[S]o+Km(app) and Km(app)=Km(1+ [I]/ Ki(app)). 
3.7. Crystallization 
Crystals were obtained using the hanging drop vapour diffusion method. The concentration of protein 
was 8 mg mL-1 and the concentration of inhibitor was 3.3 mM for 1, 1.7 mM for 2 (with 1.9 mM of 
pyrophosphate) and 0.98 mM for 6. The well solution for three complexes were: 1 and 2, 20% 
PEG8000, 0.1 M Tris-HCl pH 8.5 and 0.2 M MgCl2; 6 was 0.2 M Li2SO4, 0.1 M Sodium acetate pH 
4.5 and 30% PEG8000. The drop consisted of an equal volume of well solution and protein inhibitor 
complex. Prior to data collection, crystals of MtHGPRT.2 and MtHGPRT.6 complex were transferred 
to a solution that contained well solution, 20% glycerol and inhibitor with final concentration of 2.2 
mM and 4.9 mM, respectively. For compound 1, no cryoprotection was required. Crystals were cryo-
cooled in liquid nitrogen and transported to the Australian Synchrotron where they were robotically 
placed in a cryostream (100K) on beamline MX1. All X-ray data were collected remotely by Blu-Ice.36 
Data were merged and scaled using XDS.37 The structures were solved by molecular replacement in 
PHASER,38 within PHENIX 1.7.3,39 using the MtHGPRT.GMP complex (PDB: 4RHT) as the search 
model. Subsequent refinement and model building was with PHENIX 1.7.339 and COOT 0.7,40 
respectively. The structural restraints file for the inhibitors were generated by PRODRG2 Dundee 
server.41  
3.8. Mt inhibition during in vitro assay  
The potency of the inhibitors was measured by a resazurin reduction microplate assay, as previously 
described,42-43 with some alterations. Virulent Mt H37Rv was grown in Middlebrook 7H9 broth 
medium supplemented with 10% ADC, 0.5% glycerol and 0.02% tyloxapol. Cultures were grown at 37 
°C to mid-exponential phase (OD600 0.4-0.8) and diluted to OD600 0.002 in 7H9S media (Middlebrook 
7H9 with 10% ADC, 0.5% glycerol, 0.75% tween-80, 1% tryptone). 96-well microtitre plates were 
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setup with 100 µl of inhibitors, serially diluted into 7H9S media. 100 µl of diluted Mt, representing 
~2x104 CFU/mL was added to each well. Plates were incubated for five days at 37 °C. 42.5 µl of 
resazurin solution (30 µl of 0.02% resazurin, 12.5 µl of 20% Tween 80) was added to each well. 
Fluorescence was measured 24h later on a FluoroStar Omega fluorescent plate reader (BMG) with an 
excitation wavelength of 530 nm and an emission wavelength of 590 nm. Changes in fluorescence 
relative to positive control wells (H37Rv with no inhibitor) minus negative control wells (no H37Rv) 
were plotted for determination of MIC90. Hypoxic conditions are exactly the same except the plates 
were placed in a hypoxic chamber (0.1% O2). Completed hypoxic assay was read after 48 hrs post 
resazurin addition in aerobic conditions. Control assays with isoniazid were preformed in parallel to 
hypoxic killing assays. A loss of killing potential of isoniazid is a reliable indicator of bacterial 
dormancy. 
3.9. Mt inhibition assay in macrophages 
Human monocytic THP-1 cells were cultured in RPMI 1640 supplemented with 10% FBS, 0.05 mM 
β-mercaptoethanol and 2 mM glutamine, and incubated at 37 °C/5% CO2. For infection experiments, 
THP-1 (5x105 cells/mL) were plated into 96-well plates in complete RPMI media containing 50 ng/ml 
phorbol 12-myristate 13-acetate (PMA, Sigma Chemical Co, St. Louis, MO) for differentiation to 
macrophages (incubated at 37 °C/5% CO2). After 72 h, supernatants were removed and mCherry 
expressing, fluorescent H37Rv in RPMI media was used to infect the THP-1 cells at a Multiplicity of 
Infection (MOI) of 1:1 (1 bacteria/1 cell) for 2 h (37 °C/5% CO2). Cells were then washed two times 
with fresh complete RPMI media to remove extracellular bacilli.  The prodrug (Fig. 15A) was then 
added to infected macrophages at concentrations ranging from 250 µM  to 0.5 µM and incubated at 37 
°C and 5% CO2 for 4 days, and fluorescence was then recorded.  
3.10. Cytotoxicity assays in human cell lines 
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 Human lung carcinoma A549 cells were seeded in 96-well plates at 7500 cells per well, and on the 
next day the compounds were added in serial dilutions. After four days incubation at 37 °C, the cells 
were trypsinized, then counted with a Coulter Counter apparatus. The CC50 or 50% cytostatic 
concentration, defined as the compound concentration producing 50% inhibition of cell proliferation as 
compared to the no compound control, was calculated by extrapolation assuming a semi-log dose-
response effect. 
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Highlights 
• A new class of potent inhibitors of MtHGPRT, the pyrrolidine nucleoside phosphonates and 
bisphosphonates, have been discovered  
• Crystal structures of the MtHGPRT.I complexes show how these compounds bind to the active 
site. 
• A prodrug of these inhibitors arrest the growth of replicating and dormant TB cells  
 
 
